Clinical Trials Directory

Trials / Completed

CompletedNCT02332967

Safety and Efficacy of Addition of Structured Lipids in Starter Formulas

Status
Completed
Phase
N/A
Study type
Interventional
Enrollment
488 (actual)
Sponsor
Société des Produits Nestlé (SPN) · Industry
Sex
All
Age
1 Week – 4 Months
Healthy volunteers
Accepted

Summary

The primary objective of this trial is to demonstrate that infants receiving an infant formula in which 40 or 50% of the palmitic acid is in the sn-2 position have, during the first 4 months of life, stools that are softer than those of infants receiving a control formula.

Detailed description

Human milk is considered as the golden standard for infant formula. In human milk and infant formula lipids provide about 55% of energy for the infant and represent as such a major nutrient for the baby. The vast majority of the lipids in human milk is composed of triacylglycerols (98% of total lipids) and the remainder percent are phospholipids. Triglycerides are composed of the glycerol backbone to which three fatty acids are bound. In human milk, palmitate (16:0) is the major long chain saturated fatty acid representing 22% to 26% of total fatty acids, esterified to approximately 70% in sn-2 position on the glycerol backbone. Unsaturated fatty acids such as oleic acid (18:1) and linoleic acid (18:2n-6) are preferentially esterified at the 1 and 3 position. In infant formulas the major source of palmitic acid is palm oil or palm olein where palmitate is, however, preferentially in the external 1,3 positions, and mono- and polyunsaturated fatty acids are usually esterified at the 2-position of the triacylgycerol. The aim of this study is to assess the safety and efficacy of infant formula containing 40% and 50%, respectively, of palmitic acid in sn-2 position.

Conditions

Interventions

TypeNameDescription
OTHERWhey predominant starter formulaMilk powder product given to babies between 1 week and 4 months
OTHERWhey predominant starter formula + 40% palmitic acidMilk powder product containing 40% of palmitic acid
OTHERWhey predominant starter formula + 50% palmitic acidMilk powder product containing 50% of palmitic acid

Timeline

Start date
2007-07-01
Primary completion
2012-02-01
Completion
2012-09-01
First posted
2015-01-07
Last updated
2015-01-13

Source: ClinicalTrials.gov record NCT02332967. Inclusion in this directory is not an endorsement.